What changed: Male breast cancer

When this page itself was last checked or edited.

iDFS HR 0.

Trial included men.

Tamoxifen for five to ten years; aromatase inhibitor only with GnRH agonist suppression if tamoxifen is contraindicated.

Mastectomy (or breast conservation where feasible) with sentinel node biopsy; adjuvant radiotherapy by the same criteria as women; chemotherapy and HER2-directed therapy as indicated. (NCCN Category 2A)

First ASCO guideline on male breast cancer; FDA guidance on including men in breast cancer drug development.

Cardoso and colleagues (Ann Oncol 2018) characterise 1,483 men treated 1990 to 2010.

Wooster and colleagues identify BRCA2; male breast cancer is one of its hallmark phenotypes.

Early case series establish tamoxifen as the endocrine backbone.

Wainwright's review of published cases.